Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Melanoma
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Melanoma
    TopAbstracts in Melanoma 10/21/2009 - (DGNews)
    TopAbstracts in Melanoma 09/23/2009 - (DGNews)
    Study Reveals New Genetic Mutations Involved in Melanoma - (DGNews)
    TopAbstracts in Melanoma 08/26/2009 - (DGNews)
    Budesonide Fails as Diarrhoea Prophylactic in Melanoma Patients Receiving Ipilimumab - (DGNews)

    News archive

     Recent webcasts/CME - Melanoma
    • Moving Beyond Standard Therapy in Malignant Melanoma: Novel Agents and Combinations
    • Adjuvant Interferon Therapy Prolongs Relapse-Free Interval and Survival in Melanoma
    • Rational Vaccine Strategies May Better Harness the Immune System for Anticancer Response in Melanoma
    • Response May Not Be an Appropriate Endpoint for Evaluating Benefit From CTLA-4 Antagonists in Melanoma
    • Emerging Strategies for the Treatment of Metastatic Melanoma: The Role of Monoclonal Antibodies in Targeted Immunotherapy

      Webcasts/CME archive

       Recent cases - Melanoma
        Diffuse Anorectal Melanoma; Review of the Current Diagnostic and Treatment Aspects Based on a Case Report
        Malignant Melanoma Associated with a Blue Naevus: A Case Report
        Metastatic Malignant Melanoma of the Conjunctiva: A Case Report
        Delayed Malignant Melanoma Recurrence Simulating Primary Ovarian Cancer
        A 90-Year-Old Woman with an Asymptomatic Spot on Her Cheek

        Cases archive
          




        my personal edition > melanoma > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        New Melanoma Guidelines Put Emphasis on Biopsy: Presented at NCCN

        By Ed Susman

        HOLLYWOOD, F.L. -- March 20, 2006 -- Doctors writing new treatment guidelines for melanoma said the first time clinicians look at a suspicious lesion, they should consider the type of biopsy that should be undertaken.

        "Any new growth in the skin should be biopsied," said Daniel Coit, MD, co-leader, Melanoma Disease Management Team, Memorial Sloan-Kettering Cancer Center, and associate professor of medicine, Cornell University Medical School, New York, New York, United States.

        The pathology report after a case of melanoma is confirmed should provide the surgeon who will be performing the excision with the Breslow thickness, the Clark level, ulceration status, biopsy depths and marginal status, and presence of satellitosis.

        Dr. Coit said the key to a successful biopsy and a good cosmetic outcome depends on doing a complete biopsy the first time. And while the guidelines call for wide margins, exactly how wide they should be has been the subject of several clinical trials, with conflicting levels of evidence, he said.

        The authors of the NCCN guidelines found a compromise, with a margin width of 2 mm being recommended, depending upon tumor thickness. "Margins may be modified to accommodate individual anatomic or cosmetic considerations," Dr. Coit said, and noted that the guidelines suggest that for in situ melanomas, pathological confirmation of a negative peripheral margin is important.

        The preferred biopsy for melanoma biopsy is an excisional procedure with 1-3 mm margins. While the guideline authors encourage sufficient margins, if the excision is too wide, it could impact the ability of the surgeon to perform subsequent lymphatic mapping.

        Also acceptable is a full thickness incisional or punch biopsy of the clinically thickest portion of the lesion. The punch biopsy should be used in critical anatomical regions such as palms of the hand or the soles of the feet, the digits, the face, or the ear, or for very large lesions.

        A deep shave biopsy is acceptable when, in the clinicians view, the risk of melanoma is low.

        The guidelines also emphasize that the biopsy be read by someone familiar with and competent in diagnosing pigmented lesions.


        [Presentation title: Update: Melanoma Guidelines.]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send